Arzeda Achieves 99% Error-Free Protein Synthesis Efficiency, Revolutionizing De Novo Protein Manufacturing

Proteins are the foundation of life and the primary executors of life functions, with their structure and function determined by amino acid sequences. Currently, proteins capable of forming stable three-dimensional structures are almost exclusively natural proteins, whose amino acid sequences have been shaped by long-term natural evolution.

However, in the face of the diverse needs of constantly evolving modern industries and applications such as healthcare, the structure and function of natural proteins are insufficient. Therefore, de novo design of protein structures and sequences to obtain innovative proteins that are more effective, possess specific functions, and can meet various demands has become particularly important.

Traditional complex engineering tasks such as protein structure analysis and protein design face challenges like high equipment costs, long durations, and complicated experimental procedures. Bio-computation based on AI technology can analyze vast amounts of biological data to design and optimize models, enabling high-throughput and accurate acquisition of protein structures, thereby significantly accelerating protein engineering design.

Arzeda, located in Seattle, is a representative company in the field of protein design. Arzeda's machine learning system and R&D team are proficient in applying theoretical understanding of protein folding shapes and how they determine protein function, thereby enabling them to perform better.

By leveraging generative AI technology, Arzeda is able to achieve high-throughput predictions of enzyme characteristics, protein energy, and metabolic pathways. Through its proprietary synthetic biology platform, the company develops complex genetic instructions required for customized proteins and enzyme proteins. This integration of protein design with high-throughput screening represents a fundamental shift from traditional protein engineering techniques. Backed by robust computational power, Arzeda can create cellular factories with industrial-scale production capabilities.

Arzeda is a company headquartered in Seattle, USA.Private synthetic biology company,Focused on creating and manufacturing novel designer proteins and enzymes, Arzeda Corporation has developed a series of enzymes and specialty chemicals for polymers, pharmaceuticals, industrial chemicals, and other advanced applications, enabling customers to access products that are competitive in performance, cost, and sustainability.

Arzeda was founded in 2008 by three students from the laboratory of Dr. David Baker, a Nobel Prize nominee, with the aim of using high-throughput lab screening and advanced algorithms to replace or supplement existing chemical-based production methods for chemicals and materials.

Proteins are molecular machines that perform the vast majority of functions within living organisms. The rational design of protein functions forms the foundation of engineering biology. However, the chemical process of synthesizing new proteins is extremely challenging and does not yet guarantee 100% success in protein synthesis.

Arzeda's strategy is to utilize its proprietary Intelligent Protein Design Technology™ to select proteins and enzymes from scaffolds compatible with the target production host. Additionally, it employs its proprietary statistical learning software for DNA writing, Scribe™, to design protein stability and enzyme selectivity, thereby limiting by-product formation and achieving high expression., thereby creating entirely new designer proteins and enzymes more efficiently and with lower risk.

Based on the intersection of capabilities in new protein design, new biochemical substance manufacturing, and the scalable design of proteins and pathways, Arzeda is able to increase the efficiency of error-free synthesis to 98%-99%, making the production of novel proteins faster and more efficient.

On July 25, 2024, Arzeda completed its Series B financing, raising $38 million. Since its establishment, the company has raised a total of approximately $91 million in financing funds. Investors include 17 entities such as Bunge Ventures, Circulate Capital, Conti Ventures, Lewis & Clark AgriFood, and Sagana.

In addition, Arzeda has signed a joint development agreement with globally leading advanced material science companies such as W. L. Gore & Associates to further leverage the power of designer proteins, drive innovation in the field of material science, and enhance sustainability and performance benefits.

Arzeda's protein design technology is primarily applied in the protection and yield enhancement of agricultural crops, the production of functional sweeteners and ingredients, the manufacturing of advanced chemicals and materials, and the development of non-immunogenic therapeutic enzymes and enzymes for diagnostic use. The application scenarios are gradually expanding and diversifying, covering fields such as agriculture, chemical industry, pharmaceuticals, diagnostics, and food.

In the agricultural field, Arzeda applies its flexible protein construction technology to sustainable and efficient agricultural application scenarios such as crop health, crop yield, and crop protection, enhancing the added value of insecticidal peptides, biochemicals, engineered crops, and their microbiomes.

In the field of functional sweeteners and ingredients, Arzeda leverages its enzyme development and optimization to produce rare sugars, natural sweeteners, and other health-enhancing oligosaccharides, effectively reducing manufacturing costs and increasing operational flexibility in biocatalysis and fermentation processes.

At the same time, in the field of advanced chemicals and materials, by combining pathway design technology with enzyme design technology, Arzeda develops cost-effective and scalable technical processes to produce new performance molecules that cannot be obtained through natural diversity or synthetic chemistry. This enables the industrial production of performance-improved, sustainable monomers and additives, and expands the market space for chemicals and new materials.

Not only that, but also inBiopharmaceuticals and DiagnosticsArzeda's protein design technology has great potential for the innovative development of non-immunogenic therapeutic enzymes and enzymes for human diagnostic applications.

Based on the extensive potential of application scenarios and the advantages of novel protein manufacturing, Arzeda has adopted a unique commercialization path. Since its establishment, the company has mainly focused on a CRO collaborative research and development model using protein design technology, and has already collaborated withPharmaceuticals, Cosmetics,Well-known enterprises in the fields of energy and clean technology have established partnership relations.

In 2016, Arzeda and Zymergen announced a collaboration to leverage Arzeda's pathway and enzyme design technology along with Zymergen's strain construction capabilities to develop strains and technical processes for the production of novel, high-efficiency molecules and materials.

In 2020, Amyris and Arzeda entered into a joint development cooperation agreement to leverage the complementarity of the two companies' technology platforms for accelerating the development and commercialization of high-protein products. The goal of this development cooperation agreement is for Arzeda to design and develop novel enzymes with unique functionalities for Amyris, which will incorporate these new enzymes into its fermentation process to enhance the production of target high-value ingredients. In this project, in addition to receiving milestone-based payments, Arzeda will also obtain additional financial income based on the value share of early results and product commercialization.

In addition to the cooperation in the pharmaceutical field,ArzedaThere are also large-scale collaborations that have garnered industry attention in the energy and clean sectors, including strategic partnerships with BP and Unilever.

By combining AI technology with de novo protein design,ArzedaBreaking through the limitation that natural proteins cannot meet the increasingly diverse demands in industrial or medical fields, it has endowed the industry with more innovative possibilities. Through the CRO model, Arzeda has maximized the potential of its technology platform, facilitating innovation and manufacturing at the protein level across multiple fields.

Currently, in the AI + protein design and synthesis field, apart from Arzeda, foreign companies such as Pregenen, Cyrus, and Virvio, as well as Chinese companies including Baikuirui, Molecular Heart, and Liwen Research Institute, are also making continuous efforts.

AI-Assisted Synthetic Biology Protein Design: As an innovative and sustainable technology, it exhibits significant commercial potential in fields such as raw material chemicals and biopharmaceuticals. It is also gradually expanding into the agricultural and food sectors, holding immense developmental promise. We will continue to monitor the commercial trends in this field over the long term.